New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:11 EDTTEVA, SHPGTeva's generic version of Shire's Adderall XR approved by FDA
Teva (TEVA) announced that the FDA has approved its Abbreviated New Drug Application for the generic version of Shire (SHPG)ís Adderall XR Capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg capsules for the treatment of attention deficit hyperactivity disorder. Adderall XR had annual sales, including brand and generic sales, of approximately $2B in the United States.
News For TEVA;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 15, 2014
12:59 EDTSHPGShire at lows down 33% after Bloomberg says AbbVie close to dropping bid
Subscribe for More Information
12:58 EDTSHPGAbbVie close to dropping takeover bid for Shire, Bloomberg reports
12:36 EDTSHPGOn The Fly: Midday Wrap
Subscribe for More Information
10:48 EDTSHPGShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
10:02 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTSHPGOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTSHPGShire upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
07:30 EDTSHPGAbbVie review of Shire deal an 'unwelcome surprise,' says Jefferies
Subscribe for More Information
06:58 EDTSHPGAbbVie volatility elevated into reconsidering Shire merger
Subscribe for More Information
06:55 EDTSHPGShire volatility elevated into AbbVie reconsidering merger recommendation
Subscribe for More Information
05:34 EDTSHPGShire says AbbVie should proceed with recommended offer
Subscribe for More Information
October 14, 2014
19:50 EDTSHPGShire down nearly 6% following AbbVie reconsidering merger recommendation
Subscribe for More Information
19:48 EDTSHPGAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
19:46 EDTSHPGAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research
October 9, 2014
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information
05:22 EDTSHPGShire provides regulatory update on SHP 465
Subscribe for More Information
October 8, 2014
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Tevaís proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use